Frontage Laboratories announced that its new GMP manufacturing facility is now fully operational. The site opened in May 2025 and completed GMP validation in October 2025.
The facility is designed for drug development, clinical manufacturing, and commercial production. Key capabilities include:
The site includes ISO-classified GMP rooms, analytical labs, and microbiology laboratories. New equipment installed includes:
The expansion supports:
These additions reduce development timelines and improve manufacturing efficiency.
Dr. Song Li, Chairman of Frontage, highlighted faster time-to-market and end-to-end support as core benefits.
Frontage Laboratories is a US-based global CRDMO with over 25 years of experience.
The company operates 26 sites worldwide and supports regulatory approvals across major global markets.
The European Commission approved Eylea 8 mg for macular edema following retinal vein occlusion. This includes branch, central, and hemiretinal vein occlusion.
RVO is now the third approved indication for Eylea 8 mg.
RVO often causes sudden vision loss in older adults who remain professionally active.
Frequent injections create a high treatment burden for patients.
In the Phase III QUASAR study, Eylea 8 mg met its primary and key secondary endpoints.
Key outcomes:
Patients receiving Eylea 8 mg required 2–3 fewer injections on average.
More than 60% of patients reached treatment intervals of four months or longer. Forty percent achieved five-month intervals by study end.
Eylea 8 mg was well tolerated. Its safety profile matched results from previous clinical trials.
The approval expands Eylea 8 mg’s EU indications to:
Eylea 8 mg remains the only anti-VEGF approved for dosing intervals up to six months in the EU.
Elanco announced USDA approval for TruCan Ultra B (Oral). The vaccine protects dogs against Bordetella bronchiseptica.
TruCan Ultra B delivers the same protection as TruCan B Oral in half the volume. Lower volume improves comfort during vaccination.
The vaccine uses PureFil Technology. This technology:
TruCan Ultra B demonstrated:
The vaccine significantly reduced Bordetella-associated coughing.
Research shows 99% of pet owners value low-volume, highly purified vaccines. Comfort during vaccination is now a priority.
This marks the second Tru vaccine expansion in 2025. TruCan Ultra CIV H3N2/H3N8 was approved in July 2025.
Elanco’s Tru vaccine line is the first portfolio recommended by Fear Free. The vaccine is expected to launch in Q1 2026.
Elanco is a global animal health leader serving pets and farm animals worldwide. The company focuses on innovation, disease prevention, and veterinary care excellence.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!